Results 1 to 10 of about 983 (198)

Comparing objective wakefulness and vigilance tests to on-the-road driving performance in narcolepsy and idiopathic hypersomnia [PDF]

, 2021
Patients with narcolepsy or idiopathic hypersomnia (IH) are at increased risk of driving accidents. Both excessive daytime sleepiness, i.e. unwanted sleep episodes during the day, and disturbed vigilance are core features of these disorders. We tested on-
Bijlenga, D., Lammers, G.J., Overeem, S., Ramaekers, J.G., Sluiszen, N.N.J.J.M. van der, Urbanus, B., Vermeeren, A.   +6 more
core   +2 more sources

Obstructive Sleep Apnea (OSA): Diagnostic and Therapeutic Challenges: Literature Review [PDF]

Obstructive sleep apnea (OSA) is a prevalent condition with known impacts on cardiovascular and neurocognitive health, affecting nearly 1 billion individuals globally.
Naser, Maged, Nasr, Mohamed M., Shehata, Lamia H.   +2 more
core   +2 more sources

Pharmacological management of narcolepsy in children and adolescents [PDF]

, 2023
Paroxysmal Cerebral ...
Barateau, L., Bassetti, C.L.A., Bruni, O., Dauvilliers, Y., Franco, P., Gringras, P., Iranzo, A., Jennum, P., Kallweit, U., Khatami, R., Knudsen-Heier, S., Lammers, G.J., Lecendreux, M., Miano, S., Nobili, L., Partinen, M., Pizza, F., Plazzi, G., Reading, P., Sonka, K., Szakacs, A., Zenti, M.   +21 more
core   +2 more sources

A scoping review of clinical approach and personalized management of obstructive sleep apnea

Journal of Association of Pulmonologist of Tamil Nadu
Obstructive sleep apnea (OSA) is common yet frequently underdiagnosed. It not only impairs the sleep quality but also associated with multiple comorbidities. This review article aims at providing an update on the diagnosis and management of OSA through a
Nileena Namboodiripad Kakkattu Mana, Gomathi Dhamodaran, Ashok Kumar Balan, Vivekanand Vishnampettai Varadarajan, Nagarajan Ramakrishnan   +4 more
doaj   +1 more source

pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy [PDF]

, 2022
Narcolepsy is a debilitating sleep disorder that presents with excessive daytime sleepiness (EDS) and cataplexy, which is a sudden paralysis of muscle tone triggered by strong emotions such as laughing.
Alvarez, Mark, Cornett, Elyse M, Hansen, Hannah, Kakazu, Juyeon, Kaye, Adam M, Kaye, Alan D, Okuampa, David, Sarfraz, Noeen   +7 more
core   +1 more source

Treatment of narcolepsy and pregnancy: a review

Sleep Science and Practice
This is a chapter review of pregnancy state in patients with narcolepsy which aims to provide a review of literature regarding pregnancy in patients with narcolepsy, physiology of hormonal change during pregnancy on sleep, pharmacologic and non ...
Kullatham Kongpakpaisarn, Christine Won
doaj   +1 more source

SOLRIAMFETOL TITRATION AND ADMINISTRATION: DOSING AND TITRATION STRATEGIES IN PATIENTS WITH OSA STARTING SOLRIAMFETOL [PDF]

Chest, 2021
HARAMANDEEP SINGH, DANIELLE HYMAN, GREGORY PARKS, ABBY CHEN, CATHERINE FOLEY, DIANE ITO, MICHAEL THORPY   +6 more
openaire   +1 more source

REM sleep in narcolepsy [PDF]

Narcolepsy is mainly associated with excessive daytime sleepiness, but the characteristic feature is abnormal rapid eye movement (REM) sleep phenomena.
Dauvilliers, Yves, Siegel, Jerome M, Thorpy, Michael J   +2 more
core   +1 more source

ADHD - Treatment Options and Consequences of Neglect [PDF]

Purpose of Research: Attention Deficit Hyperactivity Disorder (ADHD) is one of the most frequently diagnosed neurodevelopmental disorders. It is estimated to occur in approximately 5-10% of children and adolescents.
Borkowski, Adrian, Błaszczak, Karolina, Jaroń, Aleksandra, Jastrzębska, Katarzyna, Sawicki, Mateusz, Skotnicka, Joanna, Turek, Monika, Witkowska, Maria, Wojciechowska, Klara   +8 more
core   +1 more source

Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review. [PDF]

OBJECTIVE: This systematic review provides an overview of psychiatric medications in the late stages of development (Phase III clinical trials) as of June 1, 2024.
Abdelsalam, Rasha, Chandy, Thomas, Chang, Tiffany, Danovitch, Itai, Freire, Luiza, Hedrick, Rebecca, Hirsch, Drew, Ishak, Waguih, Khan, Rida, Kim, Sarah, Meyer, Ashley, Murphy, Nathalie, Parrish, Thomas, Patel, Bhumika, Pechnick, Robert, Renteria, Sabrina, Salem, Mohamed, Steiner, Alexander, Totlani, Jayant   +18 more
core